Central Nervous System Stimulant Drugs Market Size

CNS Stimulant Drugs Market size was over USD 10.94 billion in 2024 and is anticipated to cross USD 23.91 billion by 2037, growing at more than 6.2% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of central nervous system stimulant drugs is estimated at USD 11.48 billion. The market is experiencing a robust growth trajectory, primarily propelled by the escalating prevalence of attention deficit hyperactivity disorder (ADHD).

ADHD is one of the most common neurological conditions. ADHD symptoms include inability to maintain concentration, excessive movement that is inappropriate for the situation, and impulsivity. The rise in ADHD diagnoses can be ascribed to a variety of variables, including more awareness, improved diagnostic procedures, and shifting societal expectations. As awareness campaigns and educational initiatives gain momentum, more individuals with ADHD symptoms are being identified and seeking medical intervention. Studies suggest an approximately 7% (366.3 million) adults worldwide have symptomatic ADHD.

Another factor promoting the growth of central nervous system (CNS) stimulant drugs market is the rising prevalence of sleep apnea. Sleep apnea is a potentially serious sleep disease in which breathing repeatedly stops and restarts.  It is primarily caused by chronic heart failure, hypertension, and type 2 diabetes. CNS stimulants may be used to enhance daytime wakefulness in sleep apnea patients who have persistent daytime drowsiness despite proper CPAP therapy.